The World Health Organization is set to recommend weight-loss drugs like Wegovy and Zepbound for treating obesity in adults, marking its first official backing of such medications and signaling a major shift in global health policy.
-The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first time, a memo reviewed by Reuters on Thursday shows, marking a shift in its approach to treating the global health problem.
The UN agency also called for strategies to improve access to the treatment in low- and middle-income countries.
More than a billion people now have obesity worldwide, according to the WHO, and around 70% of them live in low and middle-income countries, the World Bank estimates.
The wildly popular obesity drugs - Wegovy developed by Novo Nordisk and Zepbound by Eli Lilly - are known as GLP-1 receptor agonists, which mimic the activity of a hormone that slows digestion and helps people feel full for longer. In clinical trials, people lost 15% to 20% of their body weight, depending on the drug.
The drugs have been launched in the United States and other high-income countries like Germany and Britain.
But they can cost over $1,000 a month, and studies suggest people may have to take the drugs for the rest of their lives to keep the weight off.
The WHO, Eli Lilly and Novo Nordisk were not immediately available for comment.
The WHO's conditional recommendation will be officially released in August, as part of new guidelines on treating obesity. It is also working on separate guidelines for children and adolescents.
Separately, WHO experts will also meet next week to decide whether to include the GLP-1 drugs in the agency's essential medicines list - both to treat obesity and type 2 diabetes.
The WHO's essential medicines list is a catalogue of the drugs that should be available in all functioning health systems, and it can help make drugs more widely available in poorer countries, as experts say happened in 2002 when HIV drugs were included.
In 2023, the experts decided against adding obesity drugs to the list, with WHO saying more evidence was needed on their long-term clinical benefit.
However, in the new memo recommending their use as a treatment, the agency says it supports including them on the list this time round.
Still, the WHO also raises concerns over the cost of the drugs and calls for longer-term studies on cost-effectiveness "across all settings, including LMICs" (low- and middle-income countries).
"The same mechanisms that are used in large-scale medicine access programmes may need to be adopted," to improve access, the WHO adds, such as tiered pricing or pooled procurement.
But it also notes that the active ingredient in one of the newer drugs, semaglutide - used in Novo's Wegovy - comes off patent in some markets next year.
Several companies are planning to launch cheaper generic versions of the drugs then. Liraglutide, the active ingredient in the older generation of drugs, is already available as a lower-cost generic drug, with products approved in the U.S. and Europe, the memo adds.
Iran says the Strait of Hormuz remains under its control, rejecting U.S. President Donald Trump’s claim of “total control” over t...
Armenian Prime Minister Nikol Pashinyan has dismissed Security Council Secretary Armen Grigoryan and appointed former parliament speaker Alen Simon...
Online fast-fashion platform Shein lost a London copyright lawsuit against rival Temu on Thursday over photographs used to promote some products....
Disruption in the Strait of Hormuz has increased the strategic importance of Bab al-Mandab, raising fears that instability in both waterways could trigger a wider global energy and trade crisis.
Iran and the United States remain at loggerheads over efforts to agree a permanent end to the war in the Gulf, according to a senior Iranian source who said there had been no progress in talks to revive the interim deal agreed in June and define a timeframe to implement it.
Millions of people across Spain and Iceland are preparing on Wednesday to witness a rare total solar eclipse, when the moon will pass directly between Earth and the Sun, briefly turning daylight into darkness along a narrow path.
Start your day informed with AnewZ Morning Brief. Here are the top news stories for the 12th of August, covering the latest developments.
Iran says the Strait of Hormuz remains under its control, rejecting U.S. President Donald Trump’s claim of “total control” over the strategic waterway and insisting it will not reopen until Washington fulfils its commitments under an interim deal.
The Democratic Republic of Congo says the number of confirmed Ebola cases has risen to nearly 4,500, including more than 2,060 deaths. Delayed detection, weak surveillance, funding shortages and conflict have allowed the virus to spread faster than in any previous epidemic at the same stage.
Australia warned on Monday (3 August) of a wider spread of H5N1 bird flu after its first confirmed mass mortality event among seabirds killed about 50 greater crested terns off the coast of South Australia, south of Adelaide.
Cancer patients in Sudan are struggling to access life-saving treatment as soaring medication costs, power shortages and damaged hospital infrastructure deepen the country's healthcare crisis after more than three years of war.
The world risks a resurgence of the HIV epidemic after international funding fell by nearly a fifth last year, according to a new report from UNAIDS, which warned that decades of progress against the disease could be reversed without renewed global support.
A global shift towards healthier diets, more efficient farming and reduced food waste could cut greenhouse gas emissions from agriculture-related land-use change by 85% by 2050, according to a study published last week in the journal Nature.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment